📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer. (2020)

First Author: Pickles OJ

Attributed to: Integrating innovative technologies for genotyping and phenotyping in stratified medicine funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.27681

PubMed Identifier: 32922659

Publication URI: http://europepmc.org/abstract/MED/32922659

Type: Journal Article/Review

Volume: 11

Parent Publication: Oncotarget

Issue: 34

ISSN: 1949-2553